TiumBio Co., Ltd. (KOSDAQ:321550)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,670.00
-180.00 (-2.63%)
At close: Dec 5, 2025
68.43%
Market Cap 184.61B
Revenue (ttm) 9.32B
Net Income (ttm) -11.73B
Shares Out 27.68M
EPS (ttm) -441.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 192,045
Average Volume 406,902
Open 6,910.00
Previous Close 6,850.00
Day's Range 6,540.00 - 6,910.00
52-Week Range 2,900.00 - 9,450.00
Beta 0.64
RSI 47.70
Earnings Date Nov 14, 2025

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. TiumBio Co., Ltd. was founded in 2016 and is based in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 321550
Full Company Profile

Financial Performance

In 2024, TiumBio's revenue was 6.79 billion, an increase of 38.65% compared to the previous year's 4.90 billion. Losses were -20.64 billion, 15.3% more than in 2023.

Financial Statements

News

There is no news available yet.